Skip to main content
. 2021 Aug 27;9(9):1094. doi: 10.3390/biomedicines9091094

Figure 4.

Figure 4

YKL-40 and GFAP levels in cerebral orbitofrontal cortex of AD patients and control group. Western blot analysis showing (A) YKL-40 and (B) GFAP in the cerebral orbitofrontal cortex of AD and control samples. Representative Western blots (left panels) and histograms with their densitometric analysis (right panels) are shown. Data are represented as the mean ± SEM. Differences between groups were assessed using Mann–Whitney test; * p < 0.05, ** p < 0.01.